(Q35060009)

6 August 2017

title

Role of immunotherapy in stem cell transplantation (English)

1 reference

6 August 2017

1 reference

Sally Arai

1

1 reference

6 August 2017

Hans G Klingemann

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

International Journal of Hematology

6 August 2017

published in

1 reference

6 August 2017

volume

77

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

22-28

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02982599

6 August 2017

exact match

0 references

cites work

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02982599

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02982599

In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation

21 January 2018

1 reference

12 December 2020

Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies

1 reference

12 December 2020

Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation

1 reference

12 December 2020

Immunotherapy after bone marrow transplantation

1 reference

12 December 2020

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

12 December 2020

Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma

1 reference

12 December 2020

Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines

1 reference

12 December 2020

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

1 reference

12 December 2020

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

1 reference

12 December 2020

Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells

1 reference

12 December 2020

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation

1 reference

12 December 2020

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients

1 reference

12 December 2020

Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia

1 reference

12 December 2020

Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation

1 reference

12 December 2020

Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation

1 reference

12 December 2020

The biology of natural killer cells and implications for therapy of human disease

1 reference

12 December 2020

Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells.

1 reference

12 December 2020

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies

1 reference

12 December 2020

Immunotherapy with interleukin 2 after ABMT in AML

1 reference

12 December 2020

Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia?

1 reference

12 December 2020

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.

1 reference

12 December 2020

Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]

1 reference

12 December 2020

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation

1 reference

12 December 2020

Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD.

1 reference

12 December 2020

Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice

1 reference

12 December 2020

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease

1 reference

12 December 2020

Cellular therapy of cancer with natural killer cells: will it ever work?

1 reference

12 December 2020

Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period

1 reference

12 December 2020

Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study

1 reference

12 December 2020

Specific T cell therapy in leukemia

1 reference

12 December 2020

Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia

1 reference

12 December 2020

Relevance and potential of natural killer cells in stem cell transplantation

1 reference

12 December 2020

Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation

1 reference

12 December 2020

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

12 December 2020

Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity

1 reference

12 December 2020

1 reference

12 December 2020

Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation

1 reference

12 December 2020

Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.

1 reference

12 December 2020

Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

1 reference

12 December 2020

Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies

1 reference

12 December 2020

Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.

1 reference

12 December 2020

Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation

1 reference

12 December 2020

Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives

1 reference

12 December 2020

Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study

1 reference

12 December 2020

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.

1 reference

12 December 2020

Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors

1 reference

12 December 2020

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

1 reference

12 December 2020

The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.

1 reference

12 December 2020

Induction of graft-versus-host disease after autologous bone marrow transplantation.

1 reference

12 December 2020

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

1 reference

12 December 2020

Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02982599

1 reference

6 August 2017

1 reference